Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HGS Anticipates Broad SLE Patient Access For Benlysta

This article was originally published in The Pink Sheet Daily

Executive Summary

With launch just underway of its newly approved lupus drug, HGS is seeing encouraging signs early on from payers.

You may also be interested in...



The Cabilly Saga: New Patent, New Product, New Lawsuits

Genentech seeks Benlysta royalties from HGS and GSK through enforcement of the Cabilly III patent.

The Cabilly Saga: New Patent, New Product, New Lawsuits

Genentech seeks Benlysta royalties from HGS and GSK through enforcement of the Cabilly III patent.

HGSI/GSK's Benlysta Gets BLySfully Clean Labeling, Escaping Feared Restrictions

The indication is notable for what it does not contain, which is language specifically excluding African Americans or patients with severe active lupus nephritis or severe central nervous system lupus.

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel